The Alzheimer's disease neuroimaging initiative 2 PET core: 2015
Introduction This article reviews the work done in the Alzheimer's Disease Neuroimaging
Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely …
Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely …
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
G Martínez, RWM Vernooij, PF Padilla… - Cochrane Database …, 2017 - cochranelibrary.com
Background 18 F‐florbetapir uptake by brain tissue measured by positron emission
tomography (PET) is accepted by regulatory agencies like the Food and Drug Administration …
tomography (PET) is accepted by regulatory agencies like the Food and Drug Administration …
Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios
The accurate measurement of β-amyloid (Aβ) change using amyloid PET imaging is
important for Alzheimer disease research and clinical trials but poses several unique …
important for Alzheimer disease research and clinical trials but poses several unique …
[HTML][HTML] Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach
Background Inconsistent positivity thresholds, image analysis pipelines, and quantitative
outcomes are key challenges of multisite studies using more than one β-amyloid (Aβ) …
outcomes are key challenges of multisite studies using more than one β-amyloid (Aβ) …
[HTML][HTML] Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid-and 18F-FDG-PET imaging
J Ottoy, E Niemantsverdriet, J Verhaeghe… - NeuroImage: Clinical, 2019 - Elsevier
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical
phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather …
phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather …
[HTML][HTML] Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled …
S Salloway, LA Honigberg, W Cho, M Ward… - Alzheimer's research & …, 2018 - Springer
Background We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ)
immunoglobulin (Ig) G4 monoclonal antibody, on biomarkers of amyloid pathology …
immunoglobulin (Ig) G4 monoclonal antibody, on biomarkers of amyloid pathology …
Memory decline accompanies subthreshold amyloid accumulation
Objective Extensive cortical β-amyloid (Aβ positivity) has been linked to cognitive decline,
but the clinical significance of elevations in Aβ within the negative range is unknown …
but the clinical significance of elevations in Aβ within the negative range is unknown …
PETPVE12: an SPM toolbox for partial volume effects correction in brain PET–application to amyloid imaging with AV45-PET
G Gonzalez-Escamilla, C Lange, S Teipel, R Buchert… - Neuroimage, 2017 - Elsevier
Positron emission tomography (PET) allows detecting molecular brain changes in vivo.
However, the accuracy of PET is limited by partial volume effects (PVE) that affects …
However, the accuracy of PET is limited by partial volume effects (PVE) that affects …
Volumetric distribution of perivascular space in relation to mild cognitive impairment
Vascular contributions to early cognitive decline are increasingly recognized, prompting
further investigation into the nature of related changes in perivascular spaces (PVS). Using …
further investigation into the nature of related changes in perivascular spaces (PVS). Using …
[HTML][HTML] Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology
Introduction Structural magnetic resonance imaging is a marker of gray matter health and
decline that is sensitive to impaired cognition and Alzheimer's disease pathology. Prior work …
decline that is sensitive to impaired cognition and Alzheimer's disease pathology. Prior work …